John Henry Krege MD

PubMed

• Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).
  Steven E Nissen, Wei Ni, Xi Shen, Qiuqing Wang, Ann Marie Navar
  The New England Journal of Medicine. 2025-05-01
• Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis.
  Arnaud S Girard, Audrey Paulin, Hasanga D Manikpurage, Emma Lajeunesse, Marie-Annick Clavel
  Journal of the American Heart Association. 2025-03-18
• Patient-centered assessment of treatment for alpha-1 antitrypsin deficiency: literature review to identify concepts and measures for people with alpha1-antitrypsin def...
  Ekin Seçinti, Karolina Schantz, Laure Delbecque, John Krege, Rikki Mangrum
  Orphanet Journal of Rare Diseases. 2025-02-22

Journal Articles

• Fractures in Women Treated with Raloxifene or Alendronate: A Retrospective Database Analysis  
  Foster SA, Shi N, Curkendall S, Stock J, Chu B, Burge R, Diakun D, Krege JH, BMC Women's Health, 1/1/2013
• Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene  
  Cosman F, Keaveny T.M., Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH, JBMR, 1/1/2013
• Effect of Teriparatide Compared with Risedronate on Reduction of Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures  
  Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL, Osteoporos Int, 1/1/2012
• Changes in Vitamin D Metabolites during Teriparatide Treatment  
  Cosman F, Dawson-Hughes B, Wan X, Krege JH, Bone, 1/1/2012
• National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges  
  Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S, Osteoporos Int, 1/1/2012
• Teriparatide and the Risk of Nonvertebral Fractures in Women with Postmenopausal Osteoporosis  
  Krege JH, Wan X, Bone, 1/1/2012
• Long-term raloxifene for postmenopausal osteoporosis  
  Recker RR, Mitlak BM, Ni X, Krege JH, Curr Med Res Opinion, 1/1/2011
• Effects of Raloxifene and Alendronate on Bone Turnover as Assessed by Procollagen Type I N-Propeptide  
  Eastell R, Ni X, Rogers A, Krege JH, Osteoporosis International, 1/1/2011
• First Fractures Among Postmenopausal Women with Osteoporosis  
  Sontag A, Krege JH, Journal of Bone and Mineral Metabolism, 1/1/2010
• Benefits and risks of raloxifene in women with osteoporosis and no previous fracture  
  Sontag A, Wan X, Krege JH, Current Medical Research and Opinion, 1/1/2010
• Effects of Arzoxifene on Bone Mineral Density and Endometrium in Postmenopausal Women with Normal or Low Bone Mass  
  Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, Alam J, Lakshmanan M, Omizo M, Journal of Clinical Endocrinology and Metabolism, 1/1/2009
• Teriparatide Vertebral Fracture Risk Reduction Determined by Quantitative and Qualitative Radiographic Assessment  
  Prevrhal S., Krege JH, Chen P., Genant H, Black D, Current Medical Research and Opinion, 1/1/2009
• Effects of Teriparatide versus Alendronate for Treating Glucocorticoid-induced Osteoporosis: 36-month Results  
  Saag KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR, Arthritis and Rheumatism, 1/1/2009
• Vertebral Fracture Status and the World Health Organization (WHO) Risk Factors for Predicting Osteoporotic Fracture Risk  
  Chen P, Krege JH, Goltzman D, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos M., Kreiger N, Olszynski WP, Josse RG, Adachi JD, and The CaMos Research Group, Journal of Bone and Mineral Research, 1/1/2009
• Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis  
  Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH, Osteoporosis International, 1/1/2009
• Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent  
  Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH, Journal of Clinical Endocrinology and Metabolism, 1/1/2009
• Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate  
  Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH, Osteoporosis International, 1/1/2008
• Measuring serum calcium before and after teriparatide treatment: authors' response  
  Wermers RA, Cosman F, Recknor CP, Xie L, Glass EV, Krege JH, Osteoporosis International, 1/1/2008
• Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide  
  Miller PD; Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R, Journal of Clinical Endocrinology and Metabolism, 1/1/2007
• Response to Teriparatide in Patients with Baseline 25-Hydroxyvitamin D Insufficiency or Sufficiency  
  Dawson-Hughes B, Chen P, Krege JH, Journal of Clinical Endocrinology and Metabolism, 1/1/2007
• Osteosarcoma and teriparatide? [letter, essentially same as letter in CMRO in number 40]  
  Harper KD, Krege JH, Marcus R, Mitlak BH, Journal of Bone and Mineral Research, 1/1/2007
• Teriparatide in Postmenopausal Women with Osteoporosis and Impaired Renal Function  
  Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH, Osteoporosis International, 1/1/2007
• Reduced risk of back pain following teriparatide treatment: A meta-analysis  
  Nevitt MC, Chen P, Dore RK, Reginster J-Y, Kiel DP, Zanchetta JR, Glass EV, Krege JH, Osteoporosis International, 1/1/2006
• A Simple Method for Determining the Probability a New Vertebral Fracture is Present in Postmenopausal Women with Osteoporosis  
  Krege JH, Adachi JD, Siminoski KG, Misurski DA, Chen P, Osteoporosis International, 1/1/2006
• Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: A meta-analysis  
  Nevitt MC, Chen P, Kiel DP, Reginster J-Y, Dore RK, Zanchetta JR, Glass EV, Krege JH, 1/1/2006
• Join now to see all

Books/Book Chapters

• Molecular Genetics of Hypertension. 
  Chapter: Mutating genes to study hypertension. 
  Krege JHEditors: Dominiczak AF, Connell JMC, and Soubrier F.Bios Scientific Publishers, Oxford1999
• OECD Proceedings: Novel Systems for the Study of Human Disease. Europe: Organisation for Economic Co-operation and Development 
  Chapter: An experiment-based classification of blood pressure genes. 
  Krege JH1998
• Molecular Genetics and Gene Therapy of Cardiovascular Diseases. 
  Chapter: Using animal models to dissect complex traits. 
  Page 271 - 292Krege JH, Kurtz TW, Smithies OEditors: Mockrin SC.Marcel Dekker, Inc., New York, NY1996

Abstracts/Posters

• Effect of teriparatide in patients with osteoporosis with prior vertebral fracture.
  Valenzuela G, Yim D, Beall DP, Gordon M, Krege JH, Krohn K., ACR, 1/1/2014
• Relationship of spine fracture burden to reduced lung volume in postmenopausal women with osteoporosis.
  Krege JH, Kendler D, Krohn K, Genant H, Berclaz P-Y, Loghin C, ASBMR, 1/1/2014
• Very early responses of biochemical markers of bone turnover to teriparatide.
  Robins DA, Leder BZ, Krohn KD, Alam J, Murphy HL, Chiang AY, Krege JH, ASBMR, 1/1/2014
• Effect of teriparatide in patients with osteoporosis and type 2 diabetes mellitus.
  Schwartz A, Krege JH, Alam J, Schuster D, ASBMR, 1/1/2014
• Effect of prior hip fracture status in patients with osteoporosis receiving teriparatide.
  Krohn L, Valenzuela G, Lane JM, Gruber B, Alam J, Chiang AY, Krege JH, Osteoporos Int, 1/1/2014
• Hip and Spine Strength Effects of Adding Versus Switching to Teriparatide in Postmenopausal Women with Osteoporosis Treated with Prior Alendronate or Raloxifene.
  Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH, ASBMR, 1/1/2012
• Unmet Need for Osteoporosis Treatment in Real World Hip Fracture Patients.
  Johnston SS, Zhao Y, McMorrow D, Krege JH, Krohn K, ASBMR, 1/1/2012
• Genetic variants in GPR177 and LRP5 may be associated with risk of lumbar spine fracture.
  O’Brien LA, Ouyang H, Krege JH, Kohler JR, ASBMR, 1/1/2012
• Unmet Need for Osteoporosis Treatment in Real World Kyphoplasty/Vertebroplasty Patients.
  Zhao Y, Johnston SS, McMorrow D, Krohn K, Krege JH, ASBMR, 1/1/2012
• Association between teriparatide adherence and healthcare utilization and costs in real world U.S. hip fracture patients.
  Johnston SS, Zhao Y, Smith DM, McMorrow D, Krohn K, Krege JH, ISPOR, 1/1/2012
• Association between teriparatide adherence and healthcare utilization and costs in real world U.S. kyphoplasty/vertebroplasty patients.
  Zhao Y, Johnston SS, Smith DM, McMorrow D, Krege JH, Krohn K, ISPOR, 1/1/2012
• Age, Bone Mineral Density, and Spine Fracture Status for Predicting Fracture Risk.
  Krege JH, Wan X, Lentle B, Berger C, Langsetmo L, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Krieger N, Olszynski WP, Josse RG, Goltzman D and the CaMos Research Group, ASBMR, 1/1/2011
• The 3/2 Power of Bone Mineral Apparent Density.
  Wan X, Krege JH, ASBMR, 1/1/2011
• Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures.
  Hadji P, Zanchetta JR, Russo LA, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan ML, Masica DN, Mitlak BH, Stock JL, ECTS, 1/1/2011
• Algorithm for Using a Bone Formation Marker PINP to Monitor the Response to Teriparatide (TPTD) in Patients with Glucocorticoid-Induced Osteoporosis (GIO).
  Lane NE, See K, Warner MR, Krege JH, Arthritis and Rheumatism, 1/1/2010
• Effects of Raloxifene and Alendronate on Bone Turnover as Assessed by Procollagen Type I N-Propeptide (PINP).
  Eastell R, Rogers A, Ni X, Krege JH, ECTS, 1/1/2010
• Fractures in Commercial and Medicare Patients Treated with Raloxifene or Alendronate: A Retrospective Database Analysis.
  Foster SA, Curkendall S, Shi N, Stock JL, Chu B-C, Burge R, Diakun D, Krege JH, JBMR, 1/1/2010
• Teriparatide and Risk of Nonvertebral Fractures in Women with Postmenopausal Osteoporosis.
  Krege JH, Wan X, JBMR, 1/1/2010
• Relationship Between Body Composition and the Skeleton.
  Wan X, Krege JH, Jiang Y, JBMR, 1/1/2010
• PCN31 A descriptive analysis of the association between breast cancer risk, bonem mineral density, and fractures in postmenopausal women in the Canadian Multicenter Os...
  Ioannidis G, Adachi J, Burge RT, Papadimitropoulos M, Krege JH, Stock JL, Muram D, Value in Health, 1/1/2009
• Prevention of osteoporosis in postmenopausal women with normal or low bone mass treated with arzoxifene.
  Broy S, Krege JH, Bolognese M, Utian WH, Alam J, Glass EV, Stock JL, Omizo M, Am Soc Bone Miner Res, 1/1/2009
• Serum osteocalcin concentrations in patients with glucocorticoid-induced osteoporosis treated with alendronate or teriparatide.
  Eastell R, Chen P, Saag KG, Burshell AL, Warner MR, Dalsky GP, Krege JH, Bone, 1/1/2009
• Serum osteocalcin concentrations in patients with glucocorticoid-induced osteoporosis treated with alendronate or teriparatide.
  Eastell R, Chen P, Saag KG, Burshell AL, Warner MR, Dalsky GP, Krege JH, Calcif Tissue Int, 1/1/2009
• Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results.
  Devogelaer JP, Saag KG, Zanchetta JR, Adler R, Eastell R, See K, Dalsky GP, Krohn K, Krege JH, Warner MR, ECCEO Annual Meeting, 1/1/2009
• Arzoxifene in postmenopausal women with normal or low bone mass.
  Utian W, Krege JH, Bolognese M, Feldman R, Broy S, Meats D, Alam J, Lakshmanan M, Omizo M, Maturitas, 1/1/2009
• Join now to see all

Lectures

• Introduced and presented new slide decks. 
  San Diego, CA; Atlanta, GA - 1/1/2010
• Assessing Fracture Risk 
  Indianapolis, IN - 1/1/2010
• New Evista Bone Deck 
  1/1/2009
• Assessing absolute fracture risk. 
  Budapest, Hungary - 1/1/2009
• Principles of post-hoc research. 
  Carmel, CA - 1/1/2009
• Drug and protocol overviews. 
  Miami, FL; Berlin, Buenos Aires, Argentina; Sidney, Australia - 1/1/2007
• Teriparatide Inhalation Powder Clinical Development Plan 
  Indianapolis, IN - 1/1/2006
• Teriparatide safety. 
  Philadelphia, PA - 1/1/2006
• Preos-Forteo Comparison 
  Indianapolis, IN - 1/1/2006
• Overview of osteoporosis and therapies. 
  Indianapolis, IN - 1/1/2005
• Preos Competitive Workshop 
  Indianapolis, IN - 1/1/2005
• Potential new Forteo application. 
  1/1/2005
• Back pain data. 
  Barcelona, Spain - 1/1/2005
• Combination anabolic plus antiresorptive therapy. 
  Rome, Italy - 1/1/2005
• Evista and bone quality. 
  Indianapolis, IN - 1/1/2004
• Forteo data. 
  New York, NY - 1/1/2004
• PINP and Forteo data. 
  Scottsdale, AZ - 1/1/2004
• New Forteo Data 
  Ottawa, Canada - 1/1/2003
• Evista Data 
  Beaver Creek, CO - 1/1/2003
• Forteo effects on bone quality. 
  1/1/2003
• Forteo dental applications, quantitative morphometry, and radiograph initiative. 
  1/1/2003
• Fracture cascade and back pain data. 
  San Diego, CA - 1/1/2003
• Forteo efficacy in severe osteoporosis. 
  Rome, Italy - 1/1/2003
• Recruitment 
  Chicago, IL - 1/1/2003
• X in window problem. 
  Indianapolis, IN - 1/1/2003
• Join now to see all